651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster I

Combinations of high risk cytogenetic events in multiple myeloma drive distinct immune remodeling patterns and worse outcomes

Inhibition of NSD2 in t 4 14 myeloma induces changes in mitochondrial priming

Genomic and transcriptomic signatures of extramedullary multiple myeloma reveal possible drivers of therapeutic resistance

Identification of novel driver genes of multiple myeloma through genome scale CRISPR activation studies

Diverse signaling and vulnerabilities accompany distinct BTK mutations associated with clinical resistance to COVALENT non COVALENT and protacs targeting BTK in MYD88 mutated lymphomas

Deciphering the cellular hierarchy of multiple myeloma uncovers a therapeutically exploitable EP300 TBX2 axis in LILRB4 myeloma initiating cells

SKP2 CKS1B as a rational drug target in 1q21 amplified multiple myeloma

Integrative omics analysis of TP53 in multiple myeloma patients

Leveraging novel CD38 targeted antibody drug conjugates for the treatment of multiple myeloma

Epigenetic reprogramming via EZH1 2 inhibition enhances T cell mediated immunotherapies against multiple myeloma

Cell free CAR therapy BCMA CAR T cell derived exosomes exhibit potent anti myeloma activity

Single–cell analysis of BCR and transcriptome uncovers plasma cell clonal dynamics and immune exhaustion linked to daratumumab response in primary light–chain amyloidosis

Single cell DNA sequencing uncovers synergistic co mutations in multiple myeloma

Super enhancer mediated regulation of CD38 inducibility in multiple myeloma via the MAF TRIM47 RARα axis

Proof of concept and mechanistic evaluation of lbl 034 a potent GPRC5D targeting T cell engager with affinity optimized sterically engineered anti CD3 arm in a multiple myeloma xenograft mouse model

Plasma proteomic analysis as a tool for monitoring the development of ibrutinib resistance in Waldenstroem macroglobulinemia

Selective germline testing in multiple myeloma patients yields a six fold increase in actionable cancer predisposition findings Time for screening guidelines

Deciphering the IKZF1 and MAP4K2 protein interactome in RASMut multiple myeloma reveals a novel regulatory pathway of IKZF1

Altered bone marrow BM plasma amino acid AA composition reflects microenvironmental remodeling in patients with multiple myeloma MM compared to monoclonal gammopathy of unknown significance MGUS

Downregulation of midnolin mediating non ubiquitin protein degradation and its role in myelomagenesis

CRISPR ko screen identifies RARα inhibition as a strategy to increase CD38 expression in multiple myeloma and potentiate anti CD38 therapy

Single cell analysis identifies a KLF5–Neutrophil–Plasma cell axis driving immune suppression in POEMS syndrome

Long read RNA sequencing of first multiple myeloma patient cohort reveals landscape of variant expression in newly diagnosed patients from the UKMRA RADAR trial

Integrated multidisciplinary approaches to improve prognosis prediction in multiple myeloma

Preclinical evaluation of SWI SNF targeting agents in multiple myeloma including t 4 14 subtypes

The TEMPI syndrome Unique patient specific monoclonal antibodies as tools for target antigen discovery

The TEMPI syndrome Unique patient specific monoclonal antibodies as tools for target antigen discovery